Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Reparixin |
Synonyms | |
Therapy Description |
Reparixin (DF 1681Y) binds to and inhibits signaling of CXC chemokine receptor type 1 (CXCR1), which may lead to depletion of cancer stem cells (PMID: 20051626, PMID: 31924241). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Reparixin | DF 1681Y | CXCR Antagonist 4 | Reparixin (DF 1681Y) binds to and inhibits signaling of CXC chemokine receptor type 1 (CXCR1), which may lead to depletion of cancer stem cells (PMID: 20051626, PMID: 31924241). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02370238 | Phase II | Reparixin | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | Completed | USA | ITA | FRA | ESP | BEL | 2 |
NCT05835466 | Phase II | Reparixin | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Recruiting | USA | 0 |